TP53 and B-cell chronic lymphocytic leukemia: In fact, seminal translational studies have led to understand that CLL genetic features (i.e., IGHV mutational status and TP53 abnormalities) are important biomarkers of refractoriness to chemotherapy and, therefore, act as predictors for treatment choices [2,4,13,14].